ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
Peer review, writes Dr. Yara Abdou, is not a task, but a privilege, and an invaluable experience for the reviewer to enhance their critical thinking and engage in an invigorating academic community.
A spirit of clinically relevant discovery and accessible, understandable knowledge dissemination is the profound legacy, responsibility, and obligation that Rich will leave at ASCO, and we will honor him by continuing this work at the level of rigor and quality he established.
By holding its scientific program on time, ASCO and the entire oncology community make a pledge that we will continue advancing and offering the best care for our patients worldwide.
The number of new and old agents being suggested as COVID-19 therapies seems to be expanding exponentially. Dr. Donald L. Trump, Dr. Courtney W. Houchen, and Dr. Milton L. Brown highlight current investigations.
The TMPRSS2 protein has a role in both COVID-19 and in prostate cancer, suggesting intriguing avenues of inquiry for researchers engaged in the fight against COVID-19.
My coauthors and I call on every oncology caregiver and stakeholder to join us in the fight against our lack of information and help us gather the data that will be paramount to guide our practices in this new reality.
ASCO's chief medical officer Dr. Richard L. Schilsky and I discuss the refinement of cancer surgery, the critical importance of federally funded research, and ASCO's research priorities for the oncology community.
As we begin our work in 2020, I am excited that we are building on the remarkable successes of 2019, and the years before, with growing collaboration and sharpening focus.
As we celebrate the 20th anniversary of World Cancer Day this February 4, it’s important to recognize that we are making progress in addressing cancer.
As the world’s leading organization of oncology professionals who care for people with cancer, ASCO believes it is critical to understand what the public, including patients, think of, expect, and need from the nation’s cancer care system.
In an increasingly challenging research funding climate, partnerships to share resources and leverage complementary expertise have never been more important, writes Mr. Michael Burton.
Does big data have a big problem? Dr. John W. Sweetenham cautions, "There is a real danger that we legitimize flawed data sets by labelling them as 'real-world data' when they neither reflect the real world nor can we trust the data."
Blogs
ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
No Results.
Pages
Advertisement